Farmas USA

mucha tela los 70 creo yo...

y yo que creo que cierra el GAP en zona de 2....
AMRN

hasta estoy pensando si llega a esa zona entrar y todo....

yo le meto al cierre del gap SEGURO, si llegaramos a ese nivel ...

AMRN

siempre un placer ser copropietario de una empresa contigo ;-)

ja,ja, co-propietario dice!!! 

Pues nada, si cierra el gap haremos de co-propietarios!! :)

AMRN

MNKD

para los que creen en el producto y en Sanofi ... oportunidad de entrada con mucho cuidadin.

Para todos los demas, al filo ...

OCAT

Se mueve en la UE en dirección a la comercialización.<\b>

Advanced therapies - achievements and challenges

Dr Paula Salmikangas, Chair of EMA’s Committee for Advanced Therapies (CAT) and senior researcher at the Finnish Medicines Agency, presented the achievements and ongoing challenges in the area of advanced therapies, i.e. medicines that are based either on cells, genes or tissues. Five advanced therapies have been granted an EU-wide marketing authorisation since the creation of the CAT in 2009. This includes the first therapy based on stem cells in 2015. Four advanced therapies are currently under evaluation, including two cell-based, one gene-based and one tissue-based therapy.

http://www.ema.europa.eu/docs/en_GB/...C500184524.pdf

Lanza presenta en la Stemconn el 27 de abril

“Moving the First Pluripotent Stem Cell Therapies to the Clinic”<\b>
http://stemconn.org/preliminary-program/

Otra presentación el 29 de abril<\b> en la 12th Stem Cell Research & Regenerative Medicine Agenda | Stem Cell Summit 2015

http://www.giiconference.com/gtc321497/stem-cell-research-regenerative-medicine-agenda.shtml

11:10 Retinal Cells from Human Pluripotent Stem Cells: Clinical Potential<\b>

Shi-Jiang (John) Lu
Senior Director, Research
Ocata Therapeutics

Human pluripotent stem cells (hPSC) promise to provide an unlimited and reproducible source of replacement cells for human diseases. Various ocular diseases often result in blindness due to the loss of post-mitotic retinal neurons and other supporting cells. Among these diseases, retinitis pigmentosa (RP) and age-related macular degeneration (AMD) are characterized by loss of photoreceptor cells in the outer nuclear layer and retinal pigment epithelium (RPE); whereas glaucoma is characterized by optic nerve damage and death of retinal ganglion cells (RGC) that lead to irreversible loss of vision. We have developed a robust platform to generate photoreceptor progenitors, retinal ganglion cell progenitors and RPE from multiple hPSC lines. Photoreceptor progenitors derived from hPSCs expressed specific molecular markers for photoreceptor and integrated into outer nuclear layer after subretinal injection in mice, and rescued vision in blinded animals. After further maturation in vitro, hPSC-ganglion progenitors differentiated into ganglion cells. RPE derived from hPSCs were capable of extensive photoreceptor rescue in both the RCS rat and Elov14 mouse. Improvement in visual performance was 100% over untreated controls and near-normal functional measurements were recorded at >60 days in RCS rats. ACT is currently carrying out clinical trials at multiple sites (4 in the US and 2 in the UK) to establish the safety and tolerability of subretinal transplantation of hESC-RPE in patients with Stargardt's macular dystrophy and dry-AMD. hESC-RPEcells showed no signs of hyperproliferation, tumorigenicity, ectopic tissue formation, or apparent rejection after transplantation. Structural evidence confirmed hESC-RPE had attached and continued to persist, and visual improvement was observed in many of the treated eyes. These results suggest that hESC-RPE may provide a potentially safe source of cells for the treatment of a variety of retinal degenerative diseases.